AMSTAR 2 Yes	AMSTAR 2 Partial Yes	AMSTAR 2 No
Dutta/2023/Psychosis in Parkinson’s Disease and Current Management Trends—An Updated Review of Literature	1		12
Zhang/2022/Emerging role of psychosis in Parkinson’s disease: From clinical relevance to molecular mechanisms	2		11
Chen/2017/Treatment of psychotic symptoms in patients with Parkinson disease	1		12
Gogtay/2017/Pimavanserin—drug review	3		10
Touma/2017/Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: a review of the literature	4	1	8
Howland/2016/Pimavanserin: an inverse agonist antipsychotic drug	2		11
Levin/2016/Psychosis in Parkinson’s disease: identification, prevention and treatment	2		11
Pahwa/2016/A new perspective in the treatment of Parkinson’s disease psychosis	1	1	11
Hack/2014/An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting	2		11
Heim, B./2023/Pimavanserin: A Truly Effective Treatment for Parkinson’s Disease Psychosis? A Review of Interventions	2	1	10
Mantovani/2023/Treatment for cognitive and neuropsychiatric non-motor symptoms in Parkinson’s disease: current evidence and future perspectives	6	1	6
Joyce/2022/‘Adults with Parkinson’s disease and hallucinations or delusions can have treatment with clozapine if they need to’	2		11
Powell/2022/Treating hallucinations in Parkinson’s disease	2	1	10
Rissardo/2022/Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review	2	2	9
Gammon/2021Clozapine: Why is it so uniquely effective in the treatment of a range of neuropsychiatric disorders?	2	1	10
Torres-Yaghi/2021/QTc Interval Prolongation with Therapies Used to Treat Patients with Parkinson’s Disease Psychosis: A Narrative Review	2	3	8
Aringhieri, S./2018/Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences	2		11
Combs/2017/Update on the treatment of Parkinson’s disease psychosis: Role of pimavanserin	2	1	10
Hawkins/2017/Pimavanserin	1		12
Majláth/2017/Treatment possibilities for psychosis in Parkinson’s disease with an emphasis on the newly approved drug: Pimavanserin	2	1	10
Meadowcraft/2017/Pimavanserin for treatment of hallucinations and delusions associated with Parkinson disease psychosis	1	1	11
Kelberman/2016/New Pharmacological Approaches to Treating Non-Motor Symptoms of Parkinson’s Disease	2	1	10
Grover/2015/Psychiatric aspects of Parkinson’s disease	2	1	10
Aarsland/2014/Psychiatric issues in cognitive impairment	2		11
Ahlskog, J. E./2014/Parkinson disease treatment in hospitals and nursing facilities: Avoiding pitfalls	2		11
Hacksell/2014/On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis	1	1	11
Jing/2023/An Update on Nondopaminergic Treatments for Motor and Non-Motor Symptoms of Parkinson’s Disease	2	2	9
Isaacson/2022/Hallucinations and delusions associated with Parkinson’s disease psychosis: safety of current treatments and future directions	2	1	10
Weiss/2022/Hallucinations in Patients with Idiopathic Parkinson’s Disease	1		12
Segal/2021Psychosis in Parkinson’s Disease: Current Treatment Options and Impact on Patients and Caregivers	3	1	9
Sivanandy/2021/Systematic Review on Parkinson’s Disease Medications, Emphasizing on Three Recently Approved Drugs to Control Parkinson’s Symptoms	3	1	9
Wagner/2021/Efficacy and safety of clozapine in psychotic disorders-a systematic quantitative meta-review	5	3	5
Lizarraga/2020/Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease	1		12
Berardelli./2019/Treatment of psychiatric disturbances in hypokinetic movement disorders	2	1	10
Cumming/2019/Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases	2		11
Lyons/2019/Changing the treatment paradigm for Parkinson’s disease psychosis with pimavanserin	3	2	8
Black/2018/Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson’s disease psychosis: an expert consensus	2	1	10
Citrome/2018/Pimavanserin for the treatment of Parkinson’s disease psychosis: number needed to treat, number needed to harm, and likelihood to be helped or harmed	1	1	11
Friedman/2018/Pharmacological interventions for psychosis in Parkinson’s disease patients	1	1	11
Mueller/2018/Assessment and Management of Neuropsychiatric Symptoms in Parkinson’s Disease	1		12
Patel/2018/Nighttime Sleep and Daytime Sleepiness Improved With Pimavanserin During Treatment of Parkinson’s Disease Psychosis	2	1	10
Sahli/2018/Pimavanserin: novel pharmacotherapy for Parkinson’s disease psychosis	1	1	11
Bozymski/2017/Pimavanserin: A Novel Antipsychotic for Parkinson’s Disease Psychosis	2	1	10
Ffytche/2017/Psychosis in Parkinson’s Disease	1	1	11
Fredericks/2017/Parkinson’s disease and Parkinson’s disease psychosis: a perspective on the challenges, treatments, and economic burden	1	1	11
Hermanowicz/2017/The Emerging Role of Pimavanserin in the Management of Parkinson’s Disease Psychosis	1	1	11
Kianirad/2017/Pimavanserin, a novel antipsychotic for management of Parkinson’s disease psychosis	1	1	11
Schneider./2017/Parkinson’s disease psychosis: presentation, diagnosis and management	1	1	11
Chang/Psychosis in Parkinson’s Disease: Epidemiology, Pathophysiology, and Management	2	1	10
Chendo/2016/Pimavanserin for the treatment of Parkinson’s disease psychosis	1	1	11
Desmarais/2016/Quetiapine for Psychosis in Parkinson Disease and Neurodegenerative Parkinsonian Disorders: A Systematic Review	4	8	1
Divac/2016/The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson’s Disease	2	1	10
Markham, A./2016/Pimavanserin: First Global Approval	1	1	11
Ojo/2016/Current Understanding of Psychosis in Parkinson’s Disease	1	1	11
Samudra/2016/Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management	2	1	10
Bizzari/2015/Parkinson’s disease and psychoses	2	2	9
Lertxundi/2015/Adverse reactions to antipsychotics in Parkinson disease: an analysis of the Spanish pharmacovigilance database	3	1	9
Schrag/2015/New clinical trials for nonmotor manifestations of Parkinson’s disease	3		10
Broadstock/2014/Novel pharmaceuticals in the treatment of psychosis in Parkinson’s disease	1	1	11
Hacksell/2014/On the discovery and development of pimavanserin: a novel drug candidate for Parkinson’s psychosis	2		11